Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Can-Fite BioPharma has received approval from the Israeli Ministry of Health (MoH) to conduct Phase II clinical trial with orally-administered CF101 in the treatment of Glaucoma.
Subscribe to our email newsletter
Can-Fite claimed that its CF101 is a targeted drug that specifically attacks diseased or pathologic cells without compromising normal body systems, and therefore has shown a favorable safety profile to date.
CF101 is based on a scientific concept suggesting that the target of the drug (A3 adenosine receptor) is highly expressed on the surface of pathologic cells.
Can-Fite BioPharma said that medical centers in Israel are expected to enroll 40 patients with Glaucoma for the first cohort and will be treated for 16 weeks with CF101 or placebo.
The rationale for the conductance of this study is based on findings from the recently concluded Phase II study in Dry Eye, demonstrating a decrease in the intra ocular pressure in patients who were treated with CF101.
Pnina Fishman, CEO of Can-Fite, said: “Oral tablets could free patients from recurrent use of eye drops and enhance treatment efficacy. We hope and believe that CF101 will be proven effective in the treatment of Glaucoma, based on the finding that the drug decreased IOP in the dry eye syndrome patient population.”